Efficacy and safety of crizotinib in patients with ROS1 rearranged non-small cell lung cancer: a retrospective analysis.
暂无分享,去创建一个
Y. Ohe | N. Yamamoto | S. Murakami | H. Horinouchi | Y. Goto | Y. Fujiwara | S. Kanda | Y. Matsumoto | Y. Shinno | K. Masuda | J. Sato | R. Morita | T. Mizuno
[1] N. Reguart,et al. Immunotherapy for oncogenic-driven advanced non-small cell lung cancers: Is the time ripe for a change? , 2018, Cancer treatment reviews.
[2] J. Ahn,et al. Characteristics and Outcome of ROS1‐Positive Non–Small Cell Lung Cancer Patients in Routine Clinical Practice , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[3] A. Drilon,et al. Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations. , 2018, Cancer discovery.
[4] A. Drilon,et al. Entrectinib: an orally available, selective tyrosine kinase inhibitor for the treatment of NTRK, ROS1, and ALK fusion-positive solid tumors , 2018, Therapeutics and clinical risk management.
[5] Kenneth L. Jones,et al. Resistance Mechanisms to Targeted Therapies in ROS1+ and ALK+ Non–small Cell Lung Cancer , 2018, Clinical Cancer Research.
[6] Y. Fujiwara,et al. Appearance of a BRAF Mutation Conferring Resistance to Crizotinib in Non-Small Cell Lung Cancer Harboring Oncogenic ROS1 Fusion. , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[7] T. Yamanaka,et al. Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non-Small-Cell Lung Cancer. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] A. Shaw,et al. Lorlatinib in ALK- or ROS1-rearranged non-small cell lung cancer: an international, multicenter, open-label phase 1 trial , 2017, The Lancet. Oncology.
[9] A. Iafrate,et al. Patterns of Metastatic Spread and Mechanisms of Resistance to Crizotinib in ROS1-Positive Non-Small-Cell Lung Cancer. , 2017, JCO precision oncology.
[10] A. Mahajan,et al. ROS1 rearranged nonsmall cell lung cancer and crizotinib: An Indian experience. , 2017, Indian Journal of Cancer.
[11] Xiaozhen Liu,et al. Efficacy of crizotinib and pemetrexed-based chemotherapy in Chinese NSCLC patients with ROS1 rearrangement , 2016, Oncotarget.
[12] Yiping Zhang,et al. Patients with ROS1 rearrangement‐positive non‐small‐cell lung cancer benefit from pemetrexed‐based chemotherapy , 2016, Cancer medicine.
[13] R. Camidge,et al. An Activating KIT Mutation Induces Crizotinib Resistance in ROS1‐Positive Lung Cancer , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[14] Y. Ohe,et al. Pharmacokinetic profiles of significant adverse events with crizotinib in Japanese patients with ABCB1 polymorphism , 2016, Cancer science.
[15] D. Planchard,et al. Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers , 2016, Clinical Cancer Research.
[16] Yih-Leong Chang,et al. Efficacy of Pemetrexed‐Based Chemotherapy in Patients with ROS1 Fusion–Positive Lung Adenocarcinoma Compared with in Patients Harboring Other Driver Mutations in East Asian Populations , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[17] J. Yokota,et al. Gene aberrations for precision medicine against lung adenocarcinoma , 2016, Cancer science.
[18] Roman K. Thomas,et al. Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] Dong-Wan Kim,et al. Molecular Changes Associated with Acquired Resistance to Crizotinib in ROS1-Rearranged Non–Small Cell Lung Cancer , 2015, Clinical Cancer Research.
[20] Shingo Matsumoto,et al. Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer. , 2015, Translational lung cancer research.
[21] M. Varella‐Garcia,et al. Activation of RAS family members confers resistance to ROS1 targeting drugs , 2014, Oncotarget.
[22] F. Cappuzzo,et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. , 2014, The New England journal of medicine.
[23] Jeffrey W. Clark,et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. , 2014, The New England journal of medicine.
[24] P. Bunn,et al. Resistance to ROS1 Inhibition Mediated by EGFR Pathway Activation in Non-Small Cell Lung Cancer , 2013, PloS one.
[25] J. Borrell,et al. ALK and ROS1 as a joint target for the treatment of lung cancer: a review. , 2013, Translational lung cancer research.
[26] Yuki Togashi,et al. RET, ROS1 and ALK fusions in lung cancer , 2012, Nature Medicine.
[27] Jian Yu,et al. Survey of Tyrosine Kinase Signaling Reveals ROS Kinase Fusions in Human Cholangiocarcinoma , 2011, PloS one.
[28] S. Toyooka,et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. , 2010, The Lancet. Oncology.
[29] Laura A. Sullivan,et al. Global Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung Cancer , 2007, Cell.
[30] M. Wigler,et al. Expression and rearrangement of the ROS1 gene in human glioblastoma cells. , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[31] A. Tsao,et al. ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers , 2012 .